Reldesemtiv is an investigational new drug that is being evaluated to treat amyotrophic lateral sclerosis.[1] It is a troponin activator.[2]
Clinical data | |
---|---|
Other names | CK-2127107 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H18F2N6O |
Molar mass | 384.391 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Reldesemtiv - Astellas Pharma/Cytokinetics". AdisInsight. Springer Nature Switzerland AG.
- ^ Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, et al. (October 2021). "Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function". Journal of Medicinal Chemistry. 64 (20): 14930–14941. doi:10.1021/acs.jmedchem.1c01067. PMID 34636234.